Literature DB >> 33489700

Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case.

Takeshi Sakata1, Takahiro Yoshikawa1, Takeo Nomi1, Yasuko Matsuo1, Naoki Kamitani1, Daisuke Hokuto1, Masayuki Sho1.   

Abstract

Patients with advanced unresectable hilar cholangiocarcinoma have poor prognosis, and the survival is usually short. Herein, we report a 9-year survival case of unresectable hilar cholangiocarcinoma treated with chemoradiotherapy. A 64-year-old male patient presented with hilar cholangiocarcinoma. The tumor was located in the right hepatic duct, and it extended from the bifurcation of the anterior and posterior branches to the periphery. In the left side, the tumor extended from the umbilical portion to B2 and B3. However, there was no distant metastasis. The patient was then diagnosed with locally advanced, unresectable hilar cholangiocarcinoma and was treated with chemoradiotherapy. He received a total dose of 60 Gy in 30 daily fractions via intensity-modulated radiation therapy. In addition, he received gemcitabine chemotherapy for 5 years. There has been neither re-elevation of carbohydrate antigen 19-9 levels nor tumor relapse for 5 years during chemotherapy. Therefore, gemcitabine treatment was discontinued. However, the patient experienced tumor relapse 3 years after the last chemotherapy. Hence, chemotherapy with gemcitabine and cisplatin was initiated. At present, 1 year has passed after treatment for recurrence, and the patient has survived for 9 years since the initial treatment. Herein, we report a rare case of long-term survival with chemoradiotherapy in locally advanced unresectable hilar cholangiocarcinoma. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Chemoradiotherapy; Hilar cholangiocarcinoma; Long-term survival

Year:  2020        PMID: 33489700      PMCID: PMC7797402          DOI: 10.1007/s13691-020-00445-z

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  17 in total

1.  Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy.

Authors:  Toshimi Kaido; Masayuki Imamura
Journal:  Hepatogastroenterology       Date:  2005 May-Jun

2.  Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.

Authors:  Fumito Ito; Rashmi Agni; Robert J Rettammel; Mark J Been; Clifford S Cho; David M Mahvi; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

3.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience.

Authors:  Reena Engineer; Shaesta Mehta; Nikhil Kalyani; Suresh Chaudhari; Tejas Dharia; Nitin Shetty; Supriya Chopra; Mahesh Goel; Suyash Kulkarni; Shyam Kishore Shrivastava
Journal:  J Gastrointest Oncol       Date:  2017-02

5.  Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report.

Authors:  Gerhild Becker; Felix Momm; Henning Schwacha; Norbert Hodapp; Henning Usadel; Michael Geissler; Annette Barke; Annette Schmitt-Gräff; Karl Henne; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

6.  One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008.

Authors:  Masaru Miyazaki; Fumio Kimura; Hiroaki Shimizu; Hiroyuki Yoshidome; Masayuki Otuka; Atushi Kato; Hideyuki Yoshitomi; Katsunori Furukawa; Dan Takeuchi; Tsukasa Takayashiki; Kousuke Suda; Shigetugu Takano
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-11-21       Impact factor: 7.027

7.  The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.

Authors:  Kenichi Matsuo; Flavio G Rocha; Kaori Ito; Michael I D'Angelica; Peter J Allen; Yuman Fong; Ronald P Dematteo; Mithat Gonen; Itaru Endo; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2012-06-28       Impact factor: 6.113

8.  Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience.

Authors:  Tsuyoshi Igami; Hideki Nishio; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Yuji Nimura; Masato Nagino
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-06       Impact factor: 7.027

9.  Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.

Authors:  Hao Li; Zheng-Yun Zhang; Zun-Qiang Zhou; Jiao Guan; Da-Nian Tong; Guang-Wen Zhou
Journal:  Oncotarget       Date:  2016-05-03

10.  Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients.

Authors:  Anthony T Ruys; Steven van Haelst; Olivier R Busch; Erik A Rauws; Dirk J Gouma; Thomas M van Gulik
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.